<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Pharmacol Exp Ther</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Pharmacol. Exp. Ther</journal-id>
<journal-id journal-id-type="hwp">jpet</journal-id>
<journal-id journal-id-type="pmc">J Pharmacol Exp Ther</journal-id>
<journal-id journal-id-type="publisher-id">JPET</journal-id>
<journal-title-group>
<journal-title>The Journal of Pharmacology and Experimental Therapeutics</journal-title>
</journal-title-group>
<issn pub-type="ppub">0022-3565</issn>
<issn pub-type="epub">1521-0103</issn>
<publisher>
<publisher-name>The American Society for Pharmacology and Experimental Therapeutics</publisher-name>
<publisher-loc>Bethesda, MD</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29523700</article-id>
<article-id pub-id-type="pmc">5878667</article-id>
<article-id pub-id-type="publisher-id">JPET_246991</article-id>
<article-id pub-id-type="doi">10.1124/jpet.117.246991</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Drug Discovery and Translational Medicine</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Total RNA Sequencing of Rett Syndrome Autopsy Samples Identifies the M<sub>4</sub> Muscarinic Receptor as a Novel Therapeutic Target<xref ref-type="fn" rid="FN4"><sup><inline-graphic xlink:href="sbox.jpg"></inline-graphic></sup></xref></article-title>
<alt-title alt-title-type="short">RNA-Seq of RTT Autopsies Facilitates Target Identification</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Gogliotti</surname>
<given-names>Rocco G.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fisher</surname>
<given-names>Nicole M.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Stansley</surname>
<given-names>Branden J.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jones</surname>
<given-names>Carrie K.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lindsley</surname>
<given-names>Craig W.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Conn</surname>
<given-names>P. Jeffrey</given-names>
</name>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Niswender</surname>
<given-names>Colleen M.</given-names>
</name>
</contrib>
<aff id="aff1">Departments of Pharmacology (R.G.G., N.M.F., B.J.S., C.K.J., C.W.L., P.J.C., C.M.N.) and Chemistry (C.W.L.), and Vanderbilt Center for Neuroscience Drug Discovery (R.G.G., N.M.F., B.J.S., C.K.J., C.W.L., P.J.C., C.M.N.), Vanderbilt University, Nashville, Tennessee; and Vanderbilt Kennedy Center, Vanderbilt University Medical Center, Nashville, Tennessee (P.J.C., C.M.N.)</aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><bold>Address correspondence to:</bold> Colleen Niswender, <addr-line>Department of Pharmacology, Vanderbilt University, 12478C MRB IV, Nashville, TN 37232.</addr-line> E-mail: <email>Colleen.Niswender@vanderbilt.edu</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>5</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<month>5</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>1</day>
<month>5</month>
<year>2019</year>
</pub-date>
<!-- PMC Release delay is 12 months and
						0 days and was based on the <pub-date
						pub-type="ppub"/>. -->
<volume>365</volume>
<issue>2</issue>
<fpage>291</fpage>
<lpage>300</lpage>
<history>
<date date-type="received">
<day>08</day>
<month>12</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>08</day>
<month>3</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2018 by The American Society for Pharmacology and Experimental Therapeutics</copyright-statement>
<copyright-year>2018</copyright-year>
</permissions>
<self-uri xlink:href="jpet.117.246991.pdf" xlink:title="pdf"></self-uri>
<abstract>
<p>Mutations in the <italic>MeCP2</italic> gene are responsible for the neurodevelopmental disorder Rett syndrome (RTT). MeCP2 is a DNA-binding protein whose abundance and ability to complex with histone deacetylase 3 is linked to the regulation of chromatin structure. Consequently, loss-of-function mutations in MeCP2 are predicted to have broad effects on gene expression. However, to date, studies in mouse models of RTT have identified a limited number of gene or pathway-level disruptions, and even fewer genes have been identified that could be considered amenable to classic drug discovery approaches. Here, we performed RNA sequencing (RNA-seq) on nine motor cortex and six cerebellar autopsy samples from RTT patients and controls. This approach identified 1887 significantly affected genes in the motor cortex and 2110 genes in the cerebellum, with a global trend toward increased expression. Pathway-level analysis identified enrichment in genes associated with mitogen-activated protein kinase signaling, long-term potentiation, and axon guidance. A survey of our RNA-seq results also identified a significant decrease in expression of the <italic>CHRM4</italic> gene, which encodes a receptor [muscarinic acetylcholine receptor 4 (M<sub>4</sub>)] that is the subject of multiple large drug discovery efforts for schizophrenia and Alzheimer’s disease. We confirmed that <italic>CHRM4</italic> expression was decreased in RTT patients, and, excitingly, we demonstrated that M<sub>4</sub> potentiation normalizes social and cognitive phenotypes in <italic>Mecp2<sup>+/−</sup></italic> mice. This work provides an experimental paradigm in which translationally relevant targets can be identified using transcriptomics in RTT autopsy samples, back-modeled in <italic>Mecp2<sup>+/−</sup></italic> mice, and assessed for preclinical efficacy using existing pharmacological tool compounds.</p>
</abstract>
<counts>
<fig-count count="4"></fig-count>
<table-count count="1"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="59"></ref-count>
<page-count count="10"></page-count>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name> DJS Export </meta-name>
<meta-value>v1</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
</article>
</pmc-articleset>